Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations

Keyphrases

• Active Management 20%
• Cetuximab 20%
• Clinical Incidence 20%
• Colorectal Carcinoma 20%
• EGFR Inhibitors 40%
• Emotional Anxiety 20%
• Epidermal Growth Factor Receptor Inhibitors 20%
• Erlotinib 20%
• Gastrointestinal Malignancies 100%
• Gefitinib 20%
• Management Education 20%
• Panitumumab 20%
• Skin Rash 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Cetuximab 16%
• Dermatological Agent 16%
• Epidermal Growth Factor Receptor Kinase Inhibitor 16%
• Erlotinib 16%
• Gefitinib 16%
• Panitumumab 16%